Crossman AR - Search Results

1

Levetiracetam Interferes With the L-dopa priming process in MPTP-lesioned drug-naive marmosets.

Hill MP, Brotchie JM, Crossman AR, Bezard E, Michel A, Grimée R, Klitgaard H. Hill MP, et al. Among authors: crossman ar. Clin Neuropharmacol. 2004 Jul-Aug;27(4):171-7. doi: 10.1097/01.wnf.0000135478.70905.3d. Clin Neuropharmacol. 2004. PMID: 15319703

2

Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease.

Fox SH, Henry B, Hill M, Crossman A, Brotchie J. Fox SH, et al. Mov Disord. 2002 Nov;17(6):1180-7. doi: 10.1002/mds.10289. Mov Disord. 2002. PMID: 12465055

3

Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset.

Hill MP, Bezard E, McGuire SG, Crossman AR, Brotchie JM, Michel A, Grimée R, Klitgaard H. Hill MP, et al. Among authors: crossman ar. Mov Disord. 2003 Nov;18(11):1301-5. doi: 10.1002/mds.10542. Mov Disord. 2003. PMID: 14639671

4

Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.

Hill MP, Ravenscroft P, Bezard E, Crossman AR, Brotchie JM, Michel A, Grimée R, Klitgaard H. Hill MP, et al. Among authors: crossman ar. J Pharmacol Exp Ther. 2004 Jul;310(1):386-94. doi: 10.1124/jpet.104.066191. Epub 2004 Mar 5. J Pharmacol Exp Ther. 2004. PMID: 15004218

5

Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors.

Hill MP, Ravenscroft P, McGuire SG, Brotchie JM, Crossman AR, Rochat C, Millan MJ. Hill MP, et al. Among authors: crossman ar. Mov Disord. 2006 Dec;21(12):2090-5. doi: 10.1002/mds.21106. Mov Disord. 2006. PMID: 16991143

6

Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease.

Silverdale MA, Nicholson SL, Crossman AR, Brotchie JM. Silverdale MA, et al. Among authors: crossman ar. Mov Disord. 2005 Apr;20(4):403-409. doi: 10.1002/mds.20345. Mov Disord. 2005. PMID: 15593312

7

Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease.

Segovia G, Mora F, Crossman AR, Brotchie JM. Segovia G, et al. Among authors: crossman ar. Mov Disord. 2003 Feb;18(2):138-49. doi: 10.1002/mds.10312. Mov Disord. 2003. PMID: 12539206

8

Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia.

Ravenscroft P, Chalon S, Brotchie JM, Crossman AR. Ravenscroft P, et al. Among authors: crossman ar. Exp Neurol. 2004 Jan;185(1):36-46. doi: 10.1016/j.expneurol.2003.09.001. Exp Neurol. 2004. PMID: 14697317

9

Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque.

Bezard E, Hill MP, Crossman AR, Brotchie JM, Michel A, Grimée R, Klitgaard H. Bezard E, et al. Among authors: crossman ar. Eur J Pharmacol. 2004 Feb 6;485(1-3):159-64. doi: 10.1016/j.ejphar.2003.11.065. Eur J Pharmacol. 2004. PMID: 14757136

10

Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease.

Kobylecki C, Hill MP, Crossman AR, Ravenscroft P. Kobylecki C, et al. Among authors: crossman ar. Mov Disord. 2011 Nov;26(13):2354-63. doi: 10.1002/mds.23867. Epub 2011 Sep 23. Mov Disord. 2011. PMID: 21953539

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

165 results

Search Page

Filters